版本:
中国

BRIEF-China FDA approves country's first all-oral regimen for chronic Hepatitis C

April 28 Bristol-myers Squibb Co

* China FDA approves country's first all-oral regimen for chronic Hepatitis C, daklinza (daclatasvir) in combination with sunvepra (asunaprevir)

* Bristol-Myers Squibb Co - daklinza also approved in China for use in combination with other agents, including sofosbuvir, for HCV genotypes 1-6

* Bristol-Myers Squibb Co - sofosbuvir is under review by China food and drug administration and is not currently licensed in China Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐